Berkshire Hathaway 13F: Abel Takes Hard Look at Portfolio; Sales Outweigh Purchases

Berkshire Hathaway reported $8.1 billion in net equity sales in Q1 2026, with $24.1 billion of estimated sales versus $16.0 billion of purchases, signaling a continued portfolio reduction under Greg Abel. Major disposals included Chevron ($8.2 billion), Visa ($2.7 billion), Mastercard ($2.1 billion), and UnitedHealth ($1.5 billion), while purchases centered on Alphabet Class A ($10.9 billion) and Delta Air Lines ($2.7 billion). The filing suggests a shift toward fewer, more concentrated holdings rather than a broad risk-on posture.

Analysis

This looks less like a passive 13F cleanup and more like an intentional capital-allocation signal: Berkshire is rotating away from mature, fee-sensitive financial/consumer-finance exposures and into a smaller set of higher-conviction, more duration-sensitive franchises. The second-order effect is that several of the names being reduced were crowded “quality compounders,” so the incremental seller is not just Berkshire’s dollar amount — it is the optics of a long-term, patient holder exiting, which can pressure sentiment and weaken the multiple even if fundamentals remain intact.

The biggest near-term implication is for the high-multiple payment and managed-care complex. These businesses were already vulnerable to any hint that secular growth is decelerating, and Berkshire’s trims can catalyze factor de-risking because they arrive when index and CTA flows are still tilted toward defensives/quality. For Chevron, the sale reads more like portfolio optimization than a bearish macro call, but it still removes a stable shareholder from the energy tape at a time when crude is range-bound; that increases the odds of multiple compression if oil rolls over, because there is less patient capital to absorb drawdowns.

Alphabet is the key tell: Berkshire appears to be consolidating into a concentrated platform that has more optionality and less balance-sheet or regulatory sensitivity than the names it sold. That leaves the portfolio more exposed to idiosyncratic operating execution and less to broad economic cyclicality, which is exactly what you would expect if management is prioritizing compounding over diversification. Delta is the outlier as a cyclical add, but that may be a short-duration trade on travel demand rather than a structural change in posture.

The contrarian read is that the market may overinterpret these moves as a blanket anti-financials or anti-health-care signal when it is probably more about position sizing and replacing lower-conviction cash generators with asymmetric upside. If that’s right, the best fade is not to short Berkshire-beta broadly, but to own the specific names where Berkshire’s exits remove a strategic holder and leave valuation support thinner than consensus assumes.

Key Decisions for Investors

• Short-term: fade the payment-network complex via a 1-3 month put spread on V or MA; thesis is multiple compression from a perceived long-term holder exit, with limited fundamental damage but weak near-term sentiment.
• Pair trade: long BRK.B / short a basket of the trimmed names (V, MA, AON, STZ) over 3-6 months; the trade isolates the ‘capital allocation winner’ versus the names most exposed to governance/position-sizing overhang.
• Buy CVX only on weakness, not strength: use a 6-12 month horizon and require a pullback that resets FCF yield; Berkshire’s sale lowers the stock’s defensive sponsorship, so upside likely needs crude support rather than multiple expansion.
• Go long GOOGL/GOOG versus the sold financials basket for a 6-9 month horizon; the recent accumulation suggests Berkshire sees superior compounding with lower balance-sheet risk, and the pair should benefit if market leadership stays concentrated in mega-cap quality.
• Treat DAL as a tactical trade, not a strategic long: consider a 30-60 day call spread only if jet-fuel and demand data remain stable; otherwise it is vulnerable to a quick reversal because the add looks cyclical rather than conviction-based.